Dr. John Friedewald, MD, leads clinical trials and conducts research related to biomarker use and kidney transplant innovations. He is a board-certified nephrologist with experience in numerous related niches, including transplant genomics and biomarker development, treating acute renal failure, and kidney allocation. Dr. Friedewald is a Fellow of the American Societies of Nephrology and Transplantation. He currently serves on the board of the American Society of Transplantation and holds other leadership positions in the clinical transplant community.